title: TARC Predicts PET-Normalization and Event Free Survival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated With Brentuximab Vedotin.
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D000079963:Brentuximab Vedotin; D054414:Chemokine CCL17 / Q000097:blood*; D018572:Disease-Free Survival; D006689:Hodgkin Disease / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D049268:Positron-Emission Tomography; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; C106230:CCL17 protein, human; D054414:Chemokine CCL17; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin